Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g...
| Hlavní autoři: | , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Wiley
1998-01-01
|
| Edice: | Mediators of Inflammation |
| Témata: | |
| On-line přístup: | http://dx.doi.org/10.1080/09629359891027 |